EA201690206A1 - Терапевтически активные соединения и способы их применения - Google Patents
Терапевтически активные соединения и способы их примененияInfo
- Publication number
- EA201690206A1 EA201690206A1 EA201690206A EA201690206A EA201690206A1 EA 201690206 A1 EA201690206 A1 EA 201690206A1 EA 201690206 A EA201690206 A EA 201690206A EA 201690206 A EA201690206 A EA 201690206A EA 201690206 A1 EA201690206 A1 EA 201690206A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- application
- active compounds
- therapeutically active
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Представлены соединения, применимые для лечения рака, и способы лечения рака, включающие введение субъекту, нуждающемуся в этом, соединения, описанного в данном документе.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2013/079200 WO2015003360A2 (en) | 2013-07-11 | 2013-07-11 | Therapeutically active compounds and their methods of use |
PCT/CN2014/081957 WO2015003640A1 (en) | 2013-07-11 | 2014-07-10 | Therapeutically active compounds and their methods of use |
Publications (3)
Publication Number | Publication Date |
---|---|
EA201690206A1 true EA201690206A1 (ru) | 2016-05-31 |
EA030199B1 EA030199B1 (ru) | 2018-07-31 |
EA030199B9 EA030199B9 (ru) | 2021-08-26 |
Family
ID=52279361
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201690206A EA030199B9 (ru) | 2013-07-11 | 2014-07-10 | Терапевтически активные соединения и способы их применения |
EA201890411A EA201890411A1 (ru) | 2013-07-11 | 2014-07-10 | Терапевтически активные соединения и способы их применения |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201890411A EA201890411A1 (ru) | 2013-07-11 | 2014-07-10 | Терапевтически активные соединения и способы их применения |
Country Status (34)
Country | Link |
---|---|
US (1) | US11844758B2 (ru) |
EP (2) | EP3686190A1 (ru) |
JP (4) | JP6538037B2 (ru) |
KR (2) | KR102366734B1 (ru) |
AR (1) | AR096902A1 (ru) |
AU (2) | AU2014289744C1 (ru) |
BR (2) | BR122017014843B1 (ru) |
CA (1) | CA2917358C (ru) |
CL (2) | CL2016000052A1 (ru) |
CR (2) | CR20200479A (ru) |
CY (1) | CY1122671T1 (ru) |
DK (1) | DK3019483T3 (ru) |
EA (2) | EA030199B9 (ru) |
ES (1) | ES2773321T3 (ru) |
HK (1) | HK1217948A1 (ru) |
HR (1) | HRP20200274T1 (ru) |
HU (1) | HUE047782T2 (ru) |
IL (2) | IL243494B (ru) |
LT (1) | LT3019483T (ru) |
MX (2) | MX369319B (ru) |
MY (2) | MY196418A (ru) |
NZ (1) | NZ754946A (ru) |
PE (1) | PE20160524A1 (ru) |
PH (2) | PH12016500077B1 (ru) |
PL (1) | PL3019483T3 (ru) |
PT (1) | PT3019483T (ru) |
RS (1) | RS59922B1 (ru) |
SA (2) | SA520411465B1 (ru) |
SG (1) | SG11201600185UA (ru) |
SI (1) | SI3019483T1 (ru) |
TW (3) | TWI692472B (ru) |
UA (1) | UA122387C2 (ru) |
WO (2) | WO2015003360A2 (ru) |
ZA (1) | ZA201600667B (ru) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
EP2906212A4 (en) | 2012-10-15 | 2016-06-08 | Agios Pharmaceuticals Inc | THERAPEUTIC COMPOUNDS AND COMPOSITIONS |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
EP3019480B1 (en) | 2013-07-11 | 2020-05-06 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
KR20240010105A (ko) | 2014-03-14 | 2024-01-23 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
CN104672093B (zh) * | 2015-03-22 | 2016-04-13 | 成都塞恩斯医药科技有限公司 | 一种双环丙基甲胺的制备方法 |
RU2724333C2 (ru) * | 2015-07-30 | 2020-06-23 | Чиа Тай Тяньцинь Фармасьютикэл Груп Ко., Лтд. | Производное 1,3,5-триазина и способ его применения |
EP3331866B1 (en) * | 2015-08-05 | 2023-07-26 | Les Laboratoires Servier | Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine |
US10653710B2 (en) | 2015-10-15 | 2020-05-19 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
CA3216701A1 (en) | 2015-10-15 | 2017-04-20 | Les Laboratoires Servier | Combination therapy for treating malignancies |
US9688659B2 (en) | 2015-10-21 | 2017-06-27 | NeuForm Pharmaceuticals, Inc. | Deuterated compounds for treating hematologic malignancies, and compositions and methods thereof |
WO2017140758A1 (en) | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers |
AU2017275657B2 (en) * | 2016-06-02 | 2021-08-19 | Novartis Ag | Potassium channel modulators |
CN109890806B (zh) * | 2016-07-21 | 2022-04-26 | 南京圣和药业股份有限公司 | 作为异柠檬酸脱氢酶抑制剂的化合物及其应用 |
MX2019001173A (es) * | 2016-07-28 | 2019-08-01 | Bayer Cropscience Ag | Metodo para preparar fluoroalquilnitrilos y los fluoroalquiltetrazoles correspondientes. |
US9975886B1 (en) | 2017-01-23 | 2018-05-22 | Cadent Therapeutics, Inc. | Potassium channel modulators |
EP3638236A1 (en) | 2017-06-12 | 2020-04-22 | Agios Pharmaceuticals, Inc. | Methods of treating brain tumors using combination therapy |
WO2018231796A1 (en) * | 2017-06-12 | 2018-12-20 | Agios Pharmaceuticals, Inc. | Methods of treating brain tumors using combination therapy |
CN109265444B (zh) * | 2017-07-17 | 2022-03-11 | 南京圣和药业股份有限公司 | 取代的三嗪类idh抑制剂的光学异构体及其应用 |
CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药(上海)有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
KR20200095480A (ko) | 2017-11-02 | 2020-08-10 | 아지오스 파마슈티컬스 아이엔씨. | 공결정, 그의 제약 조성물, 및 그를 포함하는 치료 방법 |
US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
BR112022026634A2 (pt) | 2020-07-21 | 2023-01-31 | Daiichi Sankyo Co Ltd | Combinação farmacêutica de temozolomida e inibidor da enzima idh1 mutante |
US11865079B2 (en) * | 2021-02-12 | 2024-01-09 | Servier Pharmaceuticals Llc | Therapeutically active compounds and their methods of use |
CA3211049A1 (en) * | 2021-02-12 | 2022-08-18 | Les Laboratoires Servier | Therapeutically active compounds and their methods of use |
CN113461660B (zh) * | 2021-06-11 | 2022-08-02 | 浙江大学 | 2,4,6-三取代-1,3,5-均三嗪类化合物及制备和应用 |
WO2023134686A1 (zh) * | 2022-01-11 | 2023-07-20 | 正大天晴药业集团股份有限公司 | 一种1,3,5-三嗪衍生物的制备方法 |
WO2023174235A1 (zh) * | 2022-03-15 | 2023-09-21 | 贝达药业股份有限公司 | 突变型idh1和idh2抑制剂及其应用 |
CN114773320A (zh) * | 2022-05-29 | 2022-07-22 | 重庆医科大学 | 1,3,5-三嗪化合物及其制备方法和用途 |
Family Cites Families (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2390529A (en) | 1942-02-03 | 1945-12-11 | Ernst A H Friedheim | Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds |
NL125676C (ru) * | 1963-02-15 | |||
BE754242A (fr) * | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
US3867383A (en) * | 1971-03-29 | 1975-02-18 | Ciba Geigy Corp | Monoanthranilatoanilino-s-triazines |
US3681332A (en) * | 1971-04-13 | 1972-08-01 | Lilly Industries Ltd | Dihalo-s-triazine compounds |
BE793501A (fr) * | 1971-12-31 | 1973-06-29 | Ciba Geigy | Composes heterocycliques et produits phytopharmaceutiques qui en contiennent |
CH606334A5 (ru) * | 1974-06-21 | 1978-10-31 | Ciba Geigy Ag | |
JPS5170779A (ja) * | 1974-12-17 | 1976-06-18 | Nippon Shinyaku Co Ltd | Shinkinaguanamidoruino seiho |
DE2715984A1 (de) | 1977-04-09 | 1978-10-26 | Basf Ag | Farbstoffzubereitungen fuer cellulose und cellulosehaltiges textilmaterial |
DE2737984A1 (de) | 1977-08-23 | 1979-03-08 | Lentia Gmbh | Verfahren zur herstellung von lagerstabilen und vergilbungsfrei einbrennbaren lackharzen |
DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
JPS5655302A (en) * | 1979-10-15 | 1981-05-15 | Hokko Chem Ind Co Ltd | Fungicide for agriculture and horticulture |
DE3103110A1 (de) * | 1981-01-30 | 1982-08-26 | Basf Ag, 6700 Ludwigshafen | Triazingruppenhaltige verbindungen |
JPS58186682A (ja) | 1982-04-27 | 1983-10-31 | 日本化薬株式会社 | セルロ−ス又はセルロ−ス含有繊維材料の染色法 |
DE3512630A1 (de) | 1985-04-06 | 1986-10-23 | Hoechst Ag, 6230 Frankfurt | Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern |
US5041443A (en) | 1989-02-21 | 1991-08-20 | Dainippon Pharmaceutical Co., Ltd. | Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof |
US5021421A (en) | 1989-03-03 | 1991-06-04 | Dainippon Pharmaceutical Co., Ltd. | 2-(1-Piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same |
DE3922735A1 (de) * | 1989-07-11 | 1991-01-24 | Hoechst Ag | Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
JPH0499768A (ja) | 1990-08-17 | 1992-03-31 | Dainippon Pharmaceut Co Ltd | 4―(4―フェニルピリジン―2―イル)ピペラジン―1―オキシド誘導体 |
JPH05140126A (ja) * | 1991-11-26 | 1993-06-08 | Hokko Chem Ind Co Ltd | トリアゾール誘導体および除草剤 |
WO1993017009A1 (en) * | 1992-02-28 | 1993-09-02 | Zenyaku Kogyo Kabushiki Kaisha | s-TRIAZINE DERIVATIVE AND REMEDY FOR ESTROGEN-DEPENDENT DISEASES CONTAINING THE SAME AS ACTIVE INGREDIENT |
US5441563A (en) | 1993-07-06 | 1995-08-15 | Armstrong World Industries, Inc. | Highly insoluble azole embossing inhibitor and the use thereof |
IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
JPH08311047A (ja) * | 1995-05-16 | 1996-11-26 | Nissan Chem Ind Ltd | シアノエチルメラミン誘導体およびその製造方法 |
FR2735127B1 (fr) | 1995-06-09 | 1997-08-22 | Pf Medicament | Nouvelles piperazines heteroaromatiques utiles comme medicaments. |
US6124381A (en) | 1995-06-15 | 2000-09-26 | Nissan Chemical Industries, Ltd. | Expoxy/acid anhydride composition |
ES2100129B1 (es) | 1995-10-11 | 1998-02-16 | Medichem Sa | Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion. |
GB9602166D0 (en) | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
WO1997028128A1 (en) | 1996-02-02 | 1997-08-07 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
JPH09291034A (ja) | 1996-02-27 | 1997-11-11 | Yoshitomi Pharmaceut Ind Ltd | 縮合ピリジン化合物およびその医薬としての用途 |
US6262113B1 (en) | 1996-03-20 | 2001-07-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
CA2252501A1 (en) | 1996-05-20 | 1997-11-27 | Darwin Discovery Limited | Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors |
US5984882A (en) | 1996-08-19 | 1999-11-16 | Angiosonics Inc. | Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy |
EP0945446A4 (en) | 1996-11-14 | 1999-12-08 | Nissan Chemical Ind Ltd | CYANOETHYLMELAMINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME |
US6399358B1 (en) | 1997-03-31 | 2002-06-04 | Thomas Jefferson University | Human gene encoding human chondroitin 6-sulfotransferase |
JPH11158073A (ja) * | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンa3拮抗剤 |
DE69814151T2 (de) * | 1997-12-12 | 2004-03-25 | Abbott Laboratories, Abbott Park | Triazin angiogenese-inhibitoren |
ATE297383T1 (de) | 1997-12-22 | 2005-06-15 | Bayer Pharmaceuticals Corp | Hemmung der p38 kinase unter verwendung von symmetrischen und asymmetrischen diphenylharnstoffen |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
AU9064598A (en) | 1998-07-10 | 2000-02-01 | Harald Groger | Precusors for pna-monomers |
US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
EP2158923B1 (en) | 1998-08-06 | 2013-02-27 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
WO2000025780A1 (en) * | 1998-10-29 | 2000-05-11 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of impdh enzyme |
UY25842A1 (es) | 1998-12-16 | 2001-04-30 | Smithkline Beecham Corp | Antagonistas de receptores de il-8 |
AU5379900A (en) | 1999-06-07 | 2000-12-28 | Shire Biochem Inc. | Thiophene integrin inhibitors |
CA2382789A1 (en) | 1999-08-27 | 2001-03-08 | Sugen, Inc. | Phosphate mimics and methods of treatment using phosphatase inhibitors |
NZ517829A (en) | 1999-09-17 | 2004-12-24 | Millennium Pharm Inc | Benzamides and related inhibitors of factor Xa |
RU2002110295A (ru) | 1999-09-17 | 2003-12-10 | Милленниум Фармасьютикалс, Инк. (Us) | Ингибиторы фактора Ха |
WO2001047921A1 (en) | 1999-12-28 | 2001-07-05 | Pharmacopeia, Inc. | Pyrimidine and triazine kinase inhibitors |
WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
US6723730B2 (en) | 2000-07-20 | 2004-04-20 | Neurogen Corporation | Capsaicin receptor ligands |
JP4113323B2 (ja) * | 2000-08-07 | 2008-07-09 | 富士フイルム株式会社 | アゾ色素及びそれを含むインクジェット記録用インク、並びにインクジェット記録方法 |
US6525091B2 (en) | 2001-03-07 | 2003-02-25 | Telik, Inc. | Substituted diarylureas as stimulators for Fas-mediated apoptosis |
EP1389194A2 (en) | 2001-04-27 | 2004-02-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
CA2445653A1 (en) | 2001-06-11 | 2002-12-19 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
HUP0402352A2 (hu) | 2001-06-19 | 2005-02-28 | Bristol-Myers Squibb Co. | Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények |
WO2003016289A1 (en) * | 2001-08-17 | 2003-02-27 | Ciba Specialty Chemicals Holding Inc. | Triazine derivatives and their use as sunscreens |
JP4753336B2 (ja) * | 2001-09-04 | 2011-08-24 | 日本化薬株式会社 | 新規アリル化合物及びその製法 |
HUP0402499A3 (en) | 2001-12-21 | 2006-06-28 | Dow Global Technologies Inc Mi | Tertiary amine modified polyols and polyurethane products made therefrom |
US6878196B2 (en) | 2002-01-15 | 2005-04-12 | Fuji Photo Film Co., Ltd. | Ink, ink jet recording method and azo compound |
EP1485381B8 (en) | 2002-03-15 | 2010-05-12 | Vertex Pharmaceuticals Incorporated | Azolylaminoazine as inhibitors of protein kinases |
TWI319387B (en) * | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
US20040067234A1 (en) | 2002-07-11 | 2004-04-08 | Paz Einat | Isocitrate dehydrogenase and uses thereof |
DK2256108T3 (en) | 2002-07-18 | 2016-04-11 | Janssen Pharmaceutica Nv | Substituted triazinkinaseinhibitorer |
JP2004083610A (ja) * | 2002-08-22 | 2004-03-18 | Fuji Photo Film Co Ltd | インクセット、インクカートリッジ、記録方法、プリンター及び記録物 |
JP2004107220A (ja) * | 2002-09-13 | 2004-04-08 | Mitsubishi Pharma Corp | TNF−α産生抑制剤 |
TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
US7361691B2 (en) | 2002-12-02 | 2008-04-22 | Arqule, Inc. | Method of treating cancers using β-lapachone or analogs or derivatives thereof |
EP1590364B1 (en) | 2002-12-16 | 2011-10-05 | Genmab A/S | Human monoclonal antibodies against interleukin 8 (il-8) |
AU2004204778B2 (en) | 2003-01-10 | 2008-05-22 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
US7358262B2 (en) | 2003-01-29 | 2008-04-15 | Whitehead Institute For Biomedical Research | Identification of genotype-selective anti-tumor agents |
WO2004074438A2 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
WO2004073619A2 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
EP1615698B1 (en) | 2003-04-11 | 2010-09-29 | High Point Pharmaceuticals, LLC | New amide derivatives and pharmaceutical use thereof |
US7115737B2 (en) | 2003-05-05 | 2006-10-03 | New York University | Solid phase synthesis of novel biaryl triazine library by suzuki cross coupling |
WO2005003103A2 (en) * | 2003-06-30 | 2005-01-13 | Astrazeneca Ab | 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases |
US7226920B2 (en) | 2003-08-06 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Aminotriazole compounds useful as inhibitors of protein kinases |
CA2542031A1 (en) | 2003-10-10 | 2005-04-21 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives for treatment of hyperproliferative disorders |
US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
MXPA06008157A (es) | 2003-12-24 | 2007-09-07 | Johnson & Johnson | Tratamiento de gliomas malignos con inhibidores de factor de crecimiento transformante-beta. |
JP2005264016A (ja) * | 2004-03-19 | 2005-09-29 | Fuji Photo Film Co Ltd | インクジェット記録用インク、インクセット及びインクジェット記録方法 |
US7335770B2 (en) | 2004-03-24 | 2008-02-26 | Reddy U5 Therapeutics, Inc. | Triazine compounds and their analogs, compositions, and methods |
GB0412526D0 (en) | 2004-06-05 | 2004-07-14 | Leuven K U Res & Dev | Type 2 diabetes |
EP2316458A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
EP1796673A2 (en) | 2004-09-23 | 2007-06-20 | Reddy US Therapeutics, Inc. | Novel pyrimidine compounds, process for their preparation and compositions containing them |
WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | N型カルシウムチャネル阻害薬 |
JP2008526723A (ja) | 2004-12-30 | 2008-07-24 | アステックス、セラピューティックス、リミテッド | Cdk、gsk及びオーロラキナーゼの活性を調節するピラゾール誘導体 |
WO2006079791A1 (en) | 2005-01-25 | 2006-08-03 | Astrazeneca Ab | Chemical compounds |
RU2435847C2 (ru) | 2005-04-11 | 2011-12-10 | Савиент Фармасьютикалз, Инк. | Вариантная форма урат-оксидазы и ее использование |
WO2006133420A2 (en) | 2005-06-08 | 2006-12-14 | Millennium Pharmaceuticals, Inc. | Treatment of patients with cancer therapy |
GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
WO2007023186A1 (en) | 2005-08-26 | 2007-03-01 | Laboratoires Serono S.A. | Pyrazine derivatives and use as pi3k inhibitors |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
JP4753363B2 (ja) | 2005-12-28 | 2011-08-24 | 株式会社ジョイコシステムズ | 遊技媒体貸出装置用設定アダプタ、遊技媒体貸出装置用設定アダプタ付き接続ケーブルおよび遊技媒体貸出システム |
WO2007095812A1 (fr) | 2006-02-27 | 2007-08-30 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Composés triazine [1,3,5] substitués, procédés de préparation et utilisations de ceux-ci |
TW200815426A (en) | 2006-06-28 | 2008-04-01 | Astrazeneca Ab | New pyridine analogues II 333 |
WO2008036835A2 (en) | 2006-09-20 | 2008-03-27 | Reddy Us Therapeutics | Methods and compositions for upregulation of peroxiredoxin activity |
CA2669117A1 (en) | 2006-10-26 | 2008-05-02 | Gary A. Flynn | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance |
HUP0600810A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
CN101679371A (zh) | 2006-12-04 | 2010-03-24 | 艾美罗股份公司 | 作为腺苷受体拮抗剂的取代的嘧啶 |
KR101472765B1 (ko) | 2006-12-08 | 2014-12-15 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 경구용 Xa 인자 억제제를 포함하는 단위 용량 제형 및 경구용 Xa 인자 억제제를 사용하는 혈전증의 치료 방법 |
US7858782B2 (en) | 2006-12-15 | 2010-12-28 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
AU2008243674B2 (en) | 2007-04-30 | 2013-02-28 | Prometic Pharma Smt Limited | "Triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives" |
CA2683152A1 (en) | 2007-06-11 | 2008-12-18 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
SI2176231T1 (sl) | 2007-07-20 | 2017-01-31 | Nerviano Medical Sciences S.R.L. | Substituirani indazolni derivati, aktivni kot kinazni inhibitorji |
EP2175933B1 (en) | 2007-07-25 | 2012-08-22 | Bristol-Myers Squibb Company | Triazine kinase inhibitors |
TW200906818A (en) | 2007-07-31 | 2009-02-16 | Astrazeneca Ab | Chemical compounds |
MX2010003918A (es) | 2007-10-10 | 2010-08-04 | Takeda Pharmaceutical | Compuesto de amida. |
DK2214487T3 (da) | 2007-10-11 | 2014-02-10 | Glaxosmithkline Llc | Nye sEH-inhibitorer og deres anvendelse |
US20120009151A1 (en) * | 2007-12-21 | 2012-01-12 | Progenics Pharmaceuticals, Inc. | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof |
EP2219646A4 (en) | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
JP5277685B2 (ja) * | 2008-03-26 | 2013-08-28 | 富士ゼロックス株式会社 | 電子写真感光体、画像形成装置、プロセスカートリッジ及び画像形成方法 |
US20090281089A1 (en) | 2008-04-11 | 2009-11-12 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
CN101575408B (zh) | 2008-05-09 | 2013-10-30 | Mca技术有限公司 | 用作阻燃剂和光稳定剂的聚三嗪基化合物 |
WO2009150462A1 (en) | 2008-06-11 | 2009-12-17 | Astrazeneca Ab | Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders |
FR2932483A1 (fr) | 2008-06-13 | 2009-12-18 | Cytomics Systems | Composes utiles pour le traitement des cancers. |
CN101307029B (zh) * | 2008-07-08 | 2011-04-13 | 浙江大学 | 2,4,6-三取代-1,3,5-三嗪类衍生物库及制备方法 |
WO2010007756A1 (ja) | 2008-07-14 | 2010-01-21 | 塩野義製薬株式会社 | Ttk阻害作用を有するピリジン誘導体 |
US20100144722A1 (en) | 2008-09-03 | 2010-06-10 | Dr. Reddy's Laboratories Ltd. | Novel heterocyclic compounds as gata modulators |
MX343226B (es) | 2008-09-03 | 2016-10-28 | The Johns Hopkins Univ * | Alteraciones geneticas en isocitrato-deshidrogenasa y otros genes en glioma maligno. |
JP2010079130A (ja) * | 2008-09-29 | 2010-04-08 | Fuji Xerox Co Ltd | 電子写真感光体、プロセスカートリッジ、及び画像形成装置 |
US20100273808A1 (en) | 2008-11-21 | 2010-10-28 | Millennium Pharmaceticals, Inc. | Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders |
JP2010181540A (ja) * | 2009-02-04 | 2010-08-19 | Fuji Xerox Co Ltd | 電子写真感光体、プロセスカートリッジ、及び画像形成装置 |
EP2394999B1 (en) | 2009-02-06 | 2014-01-29 | Nippon Shinyaku Co., Ltd. | Aminopyrazine derivative and medicine |
US20120121515A1 (en) * | 2009-03-13 | 2012-05-17 | Lenny Dang | Methods and compositions for cell-proliferation-related disorders |
PL2427441T3 (pl) | 2009-05-04 | 2017-06-30 | Agios Pharmaceuticals, Inc. | Aktywatory PKM2 do stosowania w leczeniu raka |
WO2010130638A1 (en) | 2009-05-14 | 2010-11-18 | Evotec Ag | Sulfonamide compounds, pharmaceutical compositions and uses thereof |
CN102573485B (zh) * | 2009-06-08 | 2014-11-26 | 加利福尼亚资本权益有限责任公司 | 三嗪衍生物及其治疗应用 |
JP2012529513A (ja) | 2009-06-08 | 2012-11-22 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | トリアジン誘導体類及びそれらの治療応用 |
AU2010258964B2 (en) | 2009-06-09 | 2014-09-11 | Nantbio, Inc. | Benzyl substituted triazine derivatives and their therapeutical applications |
BRPI1011527A2 (pt) | 2009-06-09 | 2016-07-26 | California Capital Equity Llc | derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas. |
WO2010144404A1 (en) | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Pyridil-triazine inhibitors of hedgehog signaling |
ES2632954T3 (es) | 2009-06-29 | 2017-09-18 | Agios Pharmaceuticals, Inc. | Derivados de quinolina-8-sulfonamida que tienen una actividad anticancerosa |
US20120197411A1 (en) | 2009-07-10 | 2012-08-02 | Milux Holding Sa | Knee joint device and method |
EP2470173B1 (en) * | 2009-08-25 | 2016-04-27 | Abraxis BioScience, LLC | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
US20120157471A1 (en) | 2009-09-01 | 2012-06-21 | Pfizer Inc. | Benzimidazole derivatives |
US20120189670A1 (en) | 2009-09-14 | 2012-07-26 | Kirkpatrick D Lynn | Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same |
JP5473851B2 (ja) * | 2009-09-30 | 2014-04-16 | 富士フイルム株式会社 | 高分子フィルム、位相差フィルム、偏光板及び液晶表示装置 |
US8652534B2 (en) | 2009-10-14 | 2014-02-18 | Berry Pharmaceuticals, LLC | Compositions and methods for treatment of mammalian skin |
WO2011050210A1 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
IN2012DN03312A (ru) | 2009-10-22 | 2015-10-23 | Fibrotech Therapeutics Pty Ltd | |
WO2011072174A1 (en) * | 2009-12-09 | 2011-06-16 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation |
NZ578968A (en) | 2010-02-10 | 2011-03-31 | Allans Sheetmetal And Engineering Services | Fuel feed system for a pellet fire |
WO2011123618A1 (en) | 2010-04-01 | 2011-10-06 | Agios Pharmaceuticals, Inc. | Methods of identifying a candidate compound |
US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
US10064885B2 (en) | 2010-07-09 | 2018-09-04 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
BR112013001122B1 (pt) | 2010-07-16 | 2021-06-08 | Agios Pharmaceuticals, Inc | composto de fórmula ii, uso do composto e composição farmacêutica compreendendo dito composto |
TWI557123B (zh) | 2010-10-21 | 2016-11-11 | 梅迪維新技術公司 | 結晶型(8S,9R)-5-氟-8-(4-氟苯基)-9-(1-甲基-1H-1,2,4-***-5-基)-8,9-二氫-2H-吡啶并[4,3,2-de]呔-3(7H)-酮甲苯磺酸鹽 |
CN103347866B (zh) * | 2010-11-29 | 2016-05-18 | 加林制药公司 | 作为治疗呼吸控制不适或疾病的呼吸***的新化合物 |
TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
EP2691391A4 (en) | 2011-03-29 | 2014-09-10 | Broad Inst Inc | COMPOUNDS AND METHODS FOR THE TREATMENT OF DISEASES RELATED TO ISOCITRATE DEHYDROGENASE |
CN103608016A (zh) | 2011-05-03 | 2014-02-26 | 安吉奥斯医药品有限公司 | 丙酮酸激酶激活剂在治疗中的用途 |
TW201636330A (zh) | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺 |
CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN102827073A (zh) * | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
WO2013004332A1 (en) * | 2011-07-07 | 2013-01-10 | Merck Patent Gmbh | Substituted azaheterocycles for the treatment of cancer |
EP3111937B1 (en) | 2011-07-08 | 2020-06-17 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for treatment of liver cancer |
WO2013016206A1 (en) * | 2011-07-22 | 2013-01-31 | University Of Louisville Research Foundation, Inc. | Anti-biofilm compounds |
AU2012313888B2 (en) * | 2011-09-27 | 2016-03-31 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH |
CN102659765B (zh) * | 2011-12-31 | 2014-09-10 | 沈阳药科大学 | 嘧啶及三嗪类化合物的制备方法和应用 |
CN115536635A (zh) * | 2012-01-06 | 2022-12-30 | 法国施维雅药厂 | 治疗活性化合物及其使用方法 |
ES2698625T3 (es) | 2012-01-19 | 2019-02-05 | Agios Pharmaceuticals Inc | Compuestos terapéuticamente activos y sus métodos de uso |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
EP2634259A1 (en) | 2012-03-01 | 2013-09-04 | Deutsches Krebsforschungszentrum | Means and methods for the determination of (D)-2-hydroxyglutarate (D2HG) |
US20150011751A1 (en) | 2012-03-09 | 2015-01-08 | Carna Biosciences, Inc. | Novel triazine derivative |
WO2014015422A1 (en) | 2012-07-27 | 2014-01-30 | Ontario Institute For Cancer Research | Cellulose-based nanoparticles for drug delivery |
EP2906212A4 (en) | 2012-10-15 | 2016-06-08 | Agios Pharmaceuticals Inc | THERAPEUTIC COMPOUNDS AND COMPOSITIONS |
CA2892045C (en) | 2012-11-21 | 2022-05-31 | Ptc Therapeutics, Inc. | Substituted reverse pyrimidine bmi-1 inhibitors |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
EP3019480B1 (en) | 2013-07-11 | 2020-05-06 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
CN105492435B (zh) | 2013-07-11 | 2018-06-29 | 安吉奥斯医药品有限公司 | 作为idh2突变体抑制剂的化合物 |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
-
2013
- 2013-07-11 WO PCT/CN2013/079200 patent/WO2015003360A2/en active Application Filing
-
2014
- 2014-07-10 ES ES14822106T patent/ES2773321T3/es active Active
- 2014-07-10 JP JP2016524672A patent/JP6538037B2/ja active Active
- 2014-07-10 CR CR20200479A patent/CR20200479A/es unknown
- 2014-07-10 SI SI201431492T patent/SI3019483T1/sl unknown
- 2014-07-10 DK DK14822106.2T patent/DK3019483T3/da active
- 2014-07-10 KR KR1020167003499A patent/KR102366734B1/ko active IP Right Grant
- 2014-07-10 NZ NZ754946A patent/NZ754946A/en unknown
- 2014-07-10 MX MX2016000360A patent/MX369319B/es active IP Right Grant
- 2014-07-10 PL PL14822106T patent/PL3019483T3/pl unknown
- 2014-07-10 EP EP19209249.2A patent/EP3686190A1/en active Pending
- 2014-07-10 PE PE2016000039A patent/PE20160524A1/es unknown
- 2014-07-10 EA EA201690206A patent/EA030199B9/ru unknown
- 2014-07-10 BR BR122017014843-5A patent/BR122017014843B1/pt active IP Right Grant
- 2014-07-10 UA UAA201601119A patent/UA122387C2/uk unknown
- 2014-07-10 LT LTEP14822106.2T patent/LT3019483T/lt unknown
- 2014-07-10 KR KR1020227005567A patent/KR102519463B1/ko active IP Right Grant
- 2014-07-10 HU HUE14822106A patent/HUE047782T2/hu unknown
- 2014-07-10 EA EA201890411A patent/EA201890411A1/ru unknown
- 2014-07-10 AU AU2014289744A patent/AU2014289744C1/en active Active
- 2014-07-10 SG SG11201600185UA patent/SG11201600185UA/en unknown
- 2014-07-10 RS RS20200156A patent/RS59922B1/sr unknown
- 2014-07-10 EP EP14822106.2A patent/EP3019483B1/en active Active
- 2014-07-10 BR BR112016000561A patent/BR112016000561B8/pt not_active IP Right Cessation
- 2014-07-10 MY MYPI2019007872A patent/MY196418A/en unknown
- 2014-07-10 PT PT148221062T patent/PT3019483T/pt unknown
- 2014-07-10 CA CA2917358A patent/CA2917358C/en active Active
- 2014-07-10 WO PCT/CN2014/081957 patent/WO2015003640A1/en active Application Filing
- 2014-07-10 MY MYPI2016000020A patent/MY175824A/en unknown
- 2014-07-11 AR ARP140102587A patent/AR096902A1/es active IP Right Grant
- 2014-07-11 TW TW103123881A patent/TWI692472B/zh active
- 2014-07-11 TW TW107138083A patent/TWI756482B/zh active
- 2014-07-11 TW TW110137062A patent/TWI759251B/zh active
-
2016
- 2016-01-07 IL IL243494A patent/IL243494B/en active IP Right Grant
- 2016-01-11 SA SA520411465A patent/SA520411465B1/ar unknown
- 2016-01-11 SA SA516370384A patent/SA516370384B1/ar unknown
- 2016-01-11 MX MX2019013140A patent/MX2019013140A/es unknown
- 2016-01-11 PH PH12016500077A patent/PH12016500077B1/en unknown
- 2016-01-11 CL CL2016000052A patent/CL2016000052A1/es unknown
- 2016-01-29 ZA ZA2016/00667A patent/ZA201600667B/en unknown
- 2016-02-11 CR CR20160069A patent/CR20160069A/es unknown
- 2016-05-25 HK HK16105978.7A patent/HK1217948A1/zh unknown
-
2017
- 2017-03-08 CL CL2017000554A patent/CL2017000554A1/es unknown
-
2019
- 2019-02-20 AU AU2019201179A patent/AU2019201179B2/en active Active
- 2019-05-30 PH PH12019501197A patent/PH12019501197A1/en unknown
- 2019-06-05 JP JP2019105001A patent/JP2019163326A/ja active Pending
- 2019-06-30 IL IL267743A patent/IL267743B/en unknown
-
2020
- 2020-02-18 CY CY20201100149T patent/CY1122671T1/el unknown
- 2020-02-18 HR HRP20200274TT patent/HRP20200274T1/hr unknown
-
2021
- 2021-01-26 US US17/158,867 patent/US11844758B2/en active Active
- 2021-05-25 JP JP2021087457A patent/JP7450581B2/ja active Active
-
2024
- 2024-03-05 JP JP2024032681A patent/JP2024057088A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201690206A1 (ru) | Терапевтически активные соединения и способы их применения | |
EA201491330A1 (ru) | Терапевтически активные соединения и способы их использования | |
EA201890204A1 (ru) | Антибактериальные соединения | |
EA201591674A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
EA201790737A1 (ru) | Комбинированная терапия | |
EA201691845A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
EA201990043A1 (ru) | Антибактериальные соединения | |
EA201790413A1 (ru) | Антитела против tigit | |
PH12015502075B1 (en) | Treatment of cataplexy | |
EA201500314A1 (ru) | Лекарственные формы энзалутамида | |
EA201591340A1 (ru) | Модулятор андрогенного рецептора и его применения | |
EA201590987A1 (ru) | Соединения и способы их применения | |
EA201691844A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
EA201590997A1 (ru) | Соединения и способы их применения | |
EA201591327A1 (ru) | Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений | |
EA201591786A1 (ru) | Монотерапия gla для применения в лечении рака | |
EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
EA201591925A1 (ru) | Терапевтические композиции и их применение | |
WO2015003355A3 (en) | Therapeutically active compounds and their methods of use | |
EA201792096A2 (ru) | РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА | |
EA201591709A1 (ru) | 5-бром-индирубины | |
EA201690376A1 (ru) | Ингибиторы дезоксицитидинкиназы | |
MX2016005473A (es) | Metodos y composiciones para mejorar la funcion renal. | |
EA201690446A1 (ru) | Лечение множественной миеломы | |
EA201690445A1 (ru) | Лечение рака |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH4A | Publication of the corrected specification to eurasian patent |